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Introduction: Due to demographic change, an increase in the frequency of Parkinson’s 2 
disease (PD) patients is expected in the future and, thus, the identification of modifiable risk 3 
factors is urgently needed. We aimed to examine the associations of body mass index (BMI) 4 
and waist circumference (WC) with incident PD. 5 
Methods: In 13 of the 23 centers of the European Prospective Investigation into Cancer and 6 
Nutrition (EPIC) study, a total of 734 incident cases of PD were identified between 1992 and 7 
2012 with a mean follow-up of 12 years. Cox proportional hazards regression was used to 8 
calculate hazard ratios (HR) with 95% confidence intervals (CI). We modelled anthropometric 9 
variables as continuous and categorical exposures and performed subgroup analyses by 10 
potential effect modifiers including sex and smoking. 11 
Results: We found no association between BMI, WC and incident PD, neither among men 12 
nor among women. Among never and former smokers, BMI and waist circumference were 13 
also not associated with PD risk. For male smokers, however, we observed a statistically 14 
significant inverse association between BMI and PD risk (HR 0.51, 95%CI: 0.30, 0.84) and 15 
the opposite for women, i.e. a significant direct association of BMI (HR 1.79, 95%CI: 1.04, 16 
3.08) and waist circumference (HR 1.64, 95%CI: 1.03, 2.61) with risk of PD. 17 
Conclusion: Our data revealed no association between excess weight and PD risk but a 18 
possible interaction between anthropometry, sex and smoking.  19 
INTRODUCTION 20 
Parkinson’s disease (PD) is the second most common late onset neurodegenerative disease, 21 
following Alzheimer’s Disease, with an incidence between 10 and 18 cases per 100,000 22 
person-years [1-3]. Incidence rates are highest in (and post) the 7th decade with age being 23 
the greatest risk factor for PD, while pathological changes preceding clinical symptomatology 24 
typically occur already at the age of 50 [4]. The disease is generally more common among 25 
men than among women [4]. Due to a rising life expectancy worldwide, the number of people 26 
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with PD are expected to appreciably increase in the near future [5]. Hence, development of 1 
effective disease modifying therapies and identification of modifiable risk factors that would 2 
allow primary prevention of PD are urgently needed [1, 2, 4]. While the precise biological 3 
mechanisms underpinning the etiology of PD still remain unknown, the disease is thought to 4 
result from complex interactions between genetic and environmental factors. A limited 5 
number of risk factors beyond age and sex have already been discovered. Those include 6 
rural living, agricultural occupation, pesticide exposure, well-water drinking, beta-blocker use, 7 
and prior head injury [1]. Alcohol consumption, calcium channel blocker use, coffee 8 
consumption and non-steroidal anti-inflammatory drug use have been associated with 9 
relative risk reductions [1], and interestingly and most controversial, numerous epidemiologic 10 
studies showed that tobacco smoking could also be a protective factor for PD [6-8]. The role 11 
of excess body weight and its association with PD risk is still unclear [1, 9, 10]. 12 
The pathological hallmark of PD is a loss of dopaminergic neurons in the substantia nigra 13 
pars compacta [1]. Of note, a decrement of dopamine - D2 – receptor availability has been 14 
reported in obese PD patients, in proportion to their body-mass-index (BMI) [11]. Obesity is 15 
known to be pro-inflammatory; thus, obesity induced chronic inflammation may lead to higher 16 
vulnerability to neurotoxins and/or increased neurotoxin levels and a decrease of dopamine 17 
receptor availability, which may increase the risk of developing PD [12]. By contrast, a low 18 
BMI has been associated with a decline in cognitive function in the elderly and has also been 19 
suggested as a predictor for PD [13]. So far, excess BMI has been investigated as a risk 20 
factor in several prospective cohort studies and summarized in two overlapping meta-21 
analyses [9, 10]. The latest meta-analysis based on 10 cohort studies did not find any 22 
consistent association between obesity and PD [9]. Waist circumference, a surrogate for 23 
visceral body fat, was not associated with risk of PD in two prospective investigations [14, 24 
15]. 25 
These inconsistencies regarding the possible relationship between anthropometric indices of 26 
adiposity and PD risk prompted us to examine the associations of two main anthropometric 27 
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indices with the future risk of PD, by sex and by smoking status, in a large European multi-1 
center population-based cohort. 2 
METHODS 3 
Study population 4 
The current study is part of the population-based European Prospective Investigation into 5 
Cancer and Nutrition (EPIC) study [16, 17]. The EPIC cohort consists of 519,978 participants 6 
(366,521 men and 153,457 women), recruited between 1992 and 2000 in 23 centers across 7 
10 European countries, mainly drawn at random from the general population with the 8 
exception of Utrecht, where participants were part of a breast cancer screening program, and 9 
Spain and Italy, where participants were recruited from the general population as well as 10 
from selected enterprises and blood banks [17]. Thirteen of the 23 centers collected 11 
information on neurodegenerative disorders at baseline during follow-up and formed the so 12 
called NeuroEPIC4PD study, with the aim to investigate risk factors of neurodegenerative 13 
disorders. The NeuroEPIC4PD study included 220,494 participants from the following 13 14 
centers in 7 of the 10 European countries: Sweden (Umeå, Malmo), the Netherlands 15 
(Utrecht), United Kingdom (Cambridge), Germany (Heidelberg), Spain (San Sebastian, 16 
Navarra, Murcia), Italy (Turin, Varese, Florence, Naples), and Greece (countrywide). The 17 
EPIC centers in Denmark, Norway and France were not included in the current study due to 18 
unavailability of data on neurodegenerative disorders. A total of 137,174 of the 19 
NeuroEPIC4PD cohort were women (62.2%) and 83,320 were men (37.8%) [16]. This study 20 
was approved by local Ethical Committees. All participants signed a consent form for the use 21 
of the obtained data.  22 
Case ascertainment and sample size 23 
To maximize sensitivity, potential PD cases were identified by each center via record linkage 24 
with hospital records, hospital discharge files, outpatient/primary health care records, drug 25 
prescription registries and/or mortality records (Umeå, Malmo, San Sebastian, Navarra, 26 
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Murcia), through active follow-up via self-reported questionnaires and/or interviews (Utrecht, 1 
Greece) or both (Cambridge, Heidelberg, Turin, Varese, Florence, Naples) [16]. In this 2 
process 1,723 potential cases of PD and Parkinson related diseases where identified and 3 
their clinical records were reviewed by neurologists specialized in movement disorders [16]. 4 
Each case was either labeled as “definite“, “very likely“, “probable“ or “possible“, based on 5 
their likelihood of diagnosis which depended on the quality of data and the confidence of the 6 
diagnosing neurologist (e.g. “definite” if the confidence of the neurologist was high and the 7 
quality of data was excellent) [16]. Cases that failed to be labeled even as possible were not 8 
qualified and were excluded from the analysis [16]. This led to overall 881 identified cases of 9 
PD, 230 participants with parkinsonian-related disorders (e.g. multiple system atrophy) and 10 
225 with unrelated conditions, while 387 potential cases were excluded because of missing 11 
clinical data [16]. We subsequently excluded 147 prevalent PD cases at baseline, leaving a 12 
total sample of 734 incident PD cases diagnosed between 1992 and 2012, with a mean 13 
follow-up time of 12 years (range: 0-21) and, thus, a total of 220,347 participants. For a more 14 
detailed description of case ascertainment methods we refer to Gallo et al. 2015 [16]. 15 
Lifestyle characteristics 16 
Data on lifestyle and diet were collected through self-administered questionnaires or 17 
interviews at baseline [17]. Information on smoking status was available for 715 out of 734 18 
incident cases of PD. Smoking was either defined as current, when the participant was 19 
smoking any number of smoking devices per day (cigars, cigarettes, pipes) at baseline, 20 
former, when the participant was ever smoking in the past, and never, when the participant 21 
has never smoked in his or her lifetime. Information on lifetime number of cigarettes/day was 22 
only obtained in 73,787 participants (including 181 PD cases) and on duration of smoking 23 
only in 107,752 participants (including 284 PD cases). Body weight and height, as well as 24 
waist and hip circumference were measured at enrolment by trained observers, using a 25 
standardized protocol in the majority of centers [17, 18]. In the Umeå sub-cohort, no data on 26 
waist and hip circumference were obtained [18]; thus, our analyses on waist circumference 27 
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were limited to 679 out of 734 cases. Details on anthropometric measurements in EPIC were 1 
described elsewhere [18]. Body-Mass-Index (BMI) was used as an indicator for general 2 
obesity and was calculated by dividing weight (in kilograms) by the square of height (in 3 
meters). Waist circumference was analyzed as an indicator for central / abdominal obesity. 4 
Statistical Analysis 5 
Cox proportional hazards regression was used to calculate hazard ratios (HR) with 95% 6 
confidence intervals (CI) with age as the time variable, PD as the outcome and adiposity 7 
indices as the exposure variables. To account for death as a competing risk, we right-8 
censored our data at end of follow-up or death, whichever occurred first. All analyses were 9 
performed for men and women separately to account for different PD prevalence by sex [4]. 10 
In the basic model, we adjusted for age at recruitment and center. We conducted a 11 
multivariable adjusted model adjusted for age at recruitment, center, highest school level as 12 
a proxy for socio-economic status, physical activity according to the Cambridge Physical 13 
Activity Index [19] (inactive, moderately inactive, moderately active, active), coffee intake 14 
(ml/day), alcohol consumption at recruitment (g/day) and in smokers additionally for age at 15 
starting smoking, number of average lifetime cigarettes per day, lifetime duration of smoking, 16 
smoking status at recruitment and time since quitting smoking (if never smoker). These 17 
potential confounders have been discussed as possible risk factors of PD [1, 9, 20]. We 18 
tested the validity of the proportional hazard assumption with Schoenfeld residuals. We 19 
performed a continuous analysis where the HR referred to a change in BMI by 5 units and in 20 
waist circumference by 10 units. In addition, we also performed categorical analyses using 21 
pre-defined cut-points for BMI (<25kg/m2, 25-30kg/m2, ≥30kg/m2 and =<26kg/m2 vs. 22 
>26kg/m2 (median)) and waist circumference (men: <94cm, 94-102cm, ≥102cm; women: 23 
<80cm, 80-88cm, ≥88cm). We did not specifically investigate underweight (BMI <18.5kg/m²) 24 
due to a limited number of PD cases (n=7) in that group. All analyses on waist circumference 25 
were adjusted for height. Validity of the linearity assumption was tested by using restricted 26 
cubic spline regression which did not show strong evidence of deviation from linearity in our 27 
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main model. Further, we conducted subgroup analyses by smoking status (never, former, 1 
current). Heterogeneity by these suspected effect modifiers was assessed with Wald-2 
statistics. In addition, we conducted a Cox regression analysis of smoking status and PD risk 3 
stratified by median BMI and median waist circumference to explore the complexity in the 4 
triangle overweight – smoking – PD. We repeated the main analyses by restricting the 5 
dataset to the “definite” and “very likely” diagnoses. To investigate possible reverse 6 
causation, we excluded diagnosed cases within the first 5 and 10 years after baseline and 7 
included cases diagnosed within 1 year prior to baseline. We did not adjust our significance 8 
value of p < 0.05 for multiple testing because we only assessed two exposures and one 9 
outcome with a total number of 16 performed analyses (excluding sensitivity analysis). All 10 
statistical analyses were conducted using SAS, version 9.4 (SAS Institute, Cary, NC). 11 
RESULTS 12 
Main characteristics of our cohort are shown in Table 1. Although the NeuroEPIC4PD-cohort 13 
included considerably more women (62%) than men (38%), numbers of PD cases in the 14 
cohort were approximately equal between men (n=378; 51%) and women (n=356; 49%), 15 
confirming the higher incidence of PD among men (cumulative incidence: 0.45% vs. 0.26%). 16 
Mean age of study participants at baseline was 62 years (range 30-77) for cases and 53 17 
years (range 19-86) for participants who did not develop PD, i.e. non-cases. Mean age of 18 
onset of PD motor symptomatology was 70 (range 41-86) years in men and 69 (range 37-87) 19 
in women. Participants who were diagnosed with PD during follow-up consumed less alcohol 20 
and coffee at baseline than the comparison group of non-PD cases, irrespective of their sex. 21 
Smoking at baseline was less common among men and women with later PD (14% and 8%, 22 
respectively) than among the non-cases (29% and 22%, respectively). 23 
Associations of overweight with risk of PD 24 
Among men and women, neither BMI (per 5kg/m², HR 0.86, 95%CI: 0.73, 1.01 and HR 1.01, 25 
95%CI 0.88, 1.15, respectively) nor waist circumference (per 10cm, HR 1.01, 95%CI 0.89, 26 
1.13 and HR 0.98, 95%CI 0.88, 1.10, respectively) were significantly associated with PD risk. 27 
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Using categorical instead of continuous variables resulted in comparable risk associations 1 
(Supplementary Tables 1 and 2). 2 
Effect Modification by Smoking Status 3 
We observed heterogeneity by smoking status (never vs. current) in the association between 4 
BMI and PD risk (men: p-het<0.001, women: p-het=0.05) (Table 2). Among never and former 5 
smokers, neither BMI nor waist circumference were significantly associated with PD risk. 6 
Among current smokers at baseline, BMI was inversely associated with risk of PD among 7 
men (HR 0.51, 95%CI: 0.30, 0.84), in contrast to a direct association in women (HR 1.79, 8 
95%CI: 1.04, 3.08, p-het <0.001 between men and women among current smokers). 9 
Associations in similar magnitude were also observed for waist circumference among 10 
smoking women (HR 1.64, 95%CI: 1.03, 2.61) but not men. 11 
Exploratory Analyses Smoking – BMI 12 
To further elucidate these complex interactions, we alternatively examined the associations 13 
of smoking status with PD risk by strata of BMI (Supplementary Table 3). In this analysis, 14 
current compared to never smoking was inversely associated with PD risk (HR 0.40, 95%CI: 15 
0.24, 0.66) among men with a BMI above 26kg/m2, but not among men with BMI ≤26kg/m2 16 
(median). In contrast, an inverse association of current smoking with PD risk was observed in 17 
leaner (BMI ≤26kg/m2; (HR 0.36, 95%CI: 0.19, 0.66), but not in more obese women. 18 
Sensitivity Analyses 19 
Exclusion of PD cases that were diagnosed within the first five or ten years (data for 10 years 20 
not shown) after baseline and inclusion of cases diagnosed within 1 years prior to baseline 21 
did either not or only marginally influence any association between anthropometric measures 22 
and risk of PD. The only exceptions are the associations of BMI and waist circumference with 23 
risk of PD among smoking women, where risk estimates became even stronger after the 24 
exclusion of those cases that were diagnosed within 5 years after baseline (Table 2). 25 
Restricting the analysis to cases with the aforementioned diagnosis probability labeled as 26 
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“very likely” or “definite” (n=397) did not result in significant associations of BMI or waist 1 
circumference with PD risk, irrespective of the participant`s smoking status (Table 2). 2 
DISCUSSION 3 
In this European cohort with more than 700 incident PD cases, we found no association 4 
between BMI, waist circumference and incident PD, neither among men nor among women. 5 
We found an association of BMI or waist circumference with PD risk that depended on 6 
individuals’ smoking status and sex but that lost significance after the exclusion of less 7 
certain cases. 8 
Among women and men, we found that BMI was not associated with risk of PD, which is in 9 
line with findings of the most recent and comprehensive meta-analysis of prospective cohort 10 
studies [9] and with the majority of published prospective cohort studies within. By contrast, 11 
two Finnish cohorts in the meta-analyses found a positive association between BMI and PD 12 
risk [21, 22]: in one the association was irrespective of smoking history [21] and in the other 13 
the association was observed only after excluding PD cases diagnosed within the first 15 14 
years of follow-up [22]. Because only a few cases in our study were diagnosed that late 15 
during follow-up (40 cases), we were unable to replicate the latter finding. In both studies, the 16 
prospective case ascertainment relied on a registry for drug costs for all PD-patients in 17 
Finland, who were diagnosed by a physician and whose diagnosis was confirmed by a 18 
neurologist of the Social Insurance Institution [21, 22]. One of these studies also re-evaluated 19 
retrospectively the diagnoses by a study neurologist which led to the exclusion of 20% of the 20 
cases [22]. Using the drug registry for case ascertainment might have led to the exclusion of 21 
mild cases of PD, as already pointed out by Hu et al. 2006 [21]. 22 
Smoking status as an effect modifier was only investigated in one of these studies but 23 
without a differentiation between current and former smokers and with no evident interaction 24 
[21]. The more recent study did not account for a possible effect modification by smoking 25 
history although there was evidence of an unadjusted difference in mean BMI (BMI among 26 
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never and past smokers: 27.2kg/m2, BMI among smokers: 25.0kg/m2) [22]. While cohorts of 1 
both studies were small (n=45,806 and n=6,715) compared to our cohort (n=220,494), they 2 
included a very high number of cases (n=526 and n=101), which is most likely the 3 
consequence of their longer average follow-up times (19 years and 22 years), as compared 4 
to 12 years in the present dataset. These study characteristics may explain the divergent 5 
findings between the Finnish cohorts and ours. A long follow-up may increase the likelihood 6 
of people changing their smoking habits and their weight prior of a possible PD diagnosis, 7 
resulting in biased risk estimates that rely on baseline assessments. However, these are 8 
mere speculations and the reasons for the divergent results remain unclear. A recently 9 
published Mendelian randomization study with 13,708 cases of PD found an inverse 10 
association of BMI with the risk of PD (OR 0.82, 95%CI: 0.69, 0.98) [23]. However, the 11 
analysis by strata of smoking status could not be performed on aggregated data and, thus, 12 
the possibility that their observed association may be largely driven by the strong interaction 13 
between smoking status, BMI and sex could not be assessed. 14 
In our study, waist circumference was associated with a 1.6-fold higher PD risk in smoking 15 
women but not in men or non-smokers, suggesting that the location of body fat in 16 
combination with smoking status might have an influence on risk of PD depending on 17 
individuals’ sex. By contrast, Chen et al. 2004 observed in two US cohorts no association 18 
between waist circumference and PD risk among ever smokers (i.e. smokers and former 19 
smokers) but a direct association in a comparable magnitude among never smoking men 20 
and women combined [14]. Palacios et al. 2011 conducted an analysis stratified by smoking 21 
status and found no association between waist circumference and PD risk, neither among 22 
never smokers nor among ever smokers in a further US cohort [15]. In contrast to our study 23 
where measurement of the majority of anthropometric indices was performed by trained 24 
observers, all three studies relied on self-reported and self-measured data on waist 25 
circumference [14, 15]. The studies did not differentiate between former and current smokers 26 
[14, 15], thus, a possible difference between those two groups could not be investigated. 27 
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Obesity has been controversially discussed in regards to its biological impact on PD: on the 1 
one hand possibly increasing the risk by decreasing the availably of dopamine receptors and 2 
increasing the vulnerably to neurotoxins [12], on the other hand leaner subjects tend to have 3 
a higher risk of cognitive decline [13] and PD patients gaining weight following deep brain 4 
stimulation [24]. The difference in prevalence between men and women let to the idea that 5 
estrogen might have an protective effect on PD [25]. Smoking has been described as a 6 
protective factor against PD [6] by weakening the effect of different neurotoxins and 7 
improving the dopamine effect in both sexes [26] which is consistent with our data (overall 8 
HR for current smokers compared to never smokers 0.49, 95%CI: 0.38, 0.63 [27]). 9 
Paradoxically, we found that in men smoking was associated with reduced PD risk only for 10 
those who were overweight (BMI >26kg/m2), whilst in women this association was observed 11 
only for those who were comparably leaner (BMI ≤26kg/m2), which clarifies, why we did not 12 
see any strong inverse association in the continuous model with an elevated BMI among 13 
smoking women. However, one has to bear in mind that number of overweight women who 14 
smoked and developed PD during follow-up was small with 17 in total. The possible 15 
interaction between smoking, BMI and sex may, indeed, result from a complex interplay of 16 
competing risks (primarily death such as in the subgroup of smoking men, where the inverse 17 
association between BMI and PD could be due to early deaths of overweight smoking men), 18 
hormones, as well as long-term effects of heavy smoking on body composition; for instance, 19 
it has been reported that sub-groups of long-term, heavy smokers are characterized by 20 
extreme leanness [28]. Also, time from cessation of smoking can impact time spent 21 
overweight, and therefore duration of adipose related inflammation. There are no obvious 22 
plausible biological explanations for the divergent results and they are subject to speculation. 23 
Is adiposity influencing the complex protective effect of smoking on PD risk depending on 24 
sex and, hence, individuals’ hormone status? Our sensitivity analysis and the lack of 25 
association between waist circumference and PD risk among male smokers show that they 26 
need to be interpreted with caution. Further investigations in well-powered studies including 27 
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biomarker assessments are necessary to not only verify our results but also to unravel the 1 
biological nature of the associations.  2 
Whatever the explanation, the associations of BMI or waist circumference with PD risk 3 
among current smokers may primarily reflect an effect of smoking, whereas the lack of 4 
association of PD risk with either BMI or waist circumference among never smokers 5 
suggests an absence of a main effect of chronic, adiposity-related inflammation with PD 6 
development.  7 
A major strength of our investigation is the largest number of PD-cases among all cohort 8 
studies on PD and its anthropometric risk factors. The diagnosis of PD was ensured through 9 
three phases of case ascertainment, increasing validity [16]. In that process 387 possible 10 
cases were excluded because of lacking clinical data, which could have led to a possible 11 
selection bias. However, we did not observe any differences between excluded cases and 12 
PD cases with respect to baseline characteristics. By contrast to other studies, we thoroughly 13 
examined the interaction of anthropometric indices with smoking and PD. Despite having the 14 
highest number of PD-cases, restricting our analyses to “very likely” or “definite” cases 15 
limited the number of available cases substantially and more detailed sub-group analyses by 16 
a combination of sex, smoking history (e.g. time since quitting smoking and number of 17 
cigarettes smoked) and anthropometry were not possible, but would have probably shed 18 
some light on the complex associations with risk of PD. However, a descriptive analysis of 19 
the average number of cigarettes consumed in different smoking sub-groups, shows, that the 20 
mean and median are very similar among those groups. A limitation which should be 21 
considered while interpreting the results is that there might be other unconsidered and 22 
unknown confounding factors that have an influence on excess weight as well as PD. Also, it 23 
is important to note, that our follow-up time was probably not long enough and our sample 24 
size not large enough to exclude PD cases diagnosed within 15 years after baseline. 25 
The literature on excess weight and risk of PD is inconsistent. Our large-scale, prospective 26 
analysis showed no association between elevated BMI or greater waist circumference and 27 
15 
 
incident PD, which suggests, that body weight does not influence the risk of being diagnosed 1 
with PD in the next five to ten years.  We detected a possible interaction by sex and smoking 2 
status at recruitment. While, among former or never smokers, an elevated BMI or waist 3 
circumference was not associated with risk of PD, overweight conferred a lower risk among 4 
smoking men but a greater risk among smoking women. Our obtained results suggest that 5 
associations between elevated BMI and PD may be driven by smoking status and that the 6 
combination of being overweight and smoking may trigger PD development differently in men 7 
and women. The possible interactions and our divergent findings merit further investigations 8 
in well-powered studies. 9 
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